Binocular and Monocular Distance-Corrected Visual Performance and Defocus Characteristics of Clareon Truplus Intraocular Lens (IOL)

Inclusion Criteria: * Able and willing to understand and sign informed consent. * Able and willing to complete all required study visits. * Diagnosed with age-related cataracts in both eyes (OU) * Bilateral age-related cataract scheduled for phacoemulsification in both eyes by a single surgeon. * Surgeon predicts postoperative best corrected distance visual acuity (BCDVA) of ≥ 20/25 or better with Manifest Refractive Spherical Equivalent (MRSE) ±0.50 D of plano and in each eye post-operatively. * Clear intraocular media aside from cataract. * Will receive TruPlus bilaterally * Postoperative residual astigmatism ≤ 0.75 D in both eyes. * Refractive target: Emmetropia OU * Patient groups agreeing to either Femtosecond Laser Assisted Cataract Surgery (FLACS) or Standard phaco Exclusion Criteria: * Ocular comorbidities affecting visual outcomes, including but not limited to: * Macular disease (e.g., Age-Related Macular Degeneration \[AMD\], Diabetic Macular Edema \[DME\], Epiretinal Membrane \[ERM\]). * Active ocular inflammation. * Any investigator-determined condition likely to confound postoperative visual performance. * Strabismus with or without amblyopia in either eye. * Prior anterior or posterior segment surgery, including corneal refractive procedures. * History of retinal detachment. * Degenerative retinal or visual disorders deemed clinically significant by the investigator. * Diagnosed glaucoma (of any stage, if deemed vision-impacting by investigator). * Systemic conditions that could affect healing or study outcomes (e.g., immunocompromised, connective tissue disease, clinically significant atopy, diabetes).